FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Vaccines | Phase III | Phase II | Pharmaxis | Genentech | Eisai

ALSO NOTED: Pharmaxis reports Phase II CF data; New Zealand publishes biotech industry stats; and much more...

> Pharmaxis announced today that a Phase II clinical trial in children with cystic fibrosis demonstrated excellent lung function improvement following three months treatment with Bronchitol that matched that achieved by the current marketed product, Genentech's rhDNase. Release

> New Zealand has release new statistics on the country's biotech industry. Release

> Malaysian officials say the country is on track to become a biotech hub by 2020. Report

> The FDA has allowed Eisai to resume a Phase I clinical trial of E2012, an Alzheimer's treatment. Release

> Big Pharma looks more and more like a big ostrich these days, Forbes suggests. The brouhaha over Vytorin and Zetia this week is a case in point. Report

Most popular this week: Lilly readies Phase III Alzheimer's trial. Report

And Finally... Researchers are pushing ahead with the first human trials of an ebola vaccine. Report

Bookmark and Share
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about Vaccines   Phase III   Phase II   Pharmaxis   Genentech   Eisai   cystic fibrosis   biotech news  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.